End-to-end CDMO services for small molecules
Small-molecule drugs continue to form the backbone of many therapeutic areas, but their development is characterized by high technical complexity and tight regulatory tolerances. Early decisions regarding synthetic route, starting materials, polymorphic form, and process parameters affect not only quality and cost, but also safety, scalability, and regulatory acceptability in later stages.
End-to-end support for small molecules
Small-molecule drug development requires broad expertise, advanced infrastructure, and continuous access to specialists in chemistry, analytics, formulation, and regulatory affairs. For many companies, it is neither cost-effective nor strategically practical to build and maintain the full scope of this capability in-house.
RISE serves as an alternative or complement to in-house R&D. We provide access to established development teams, laboratories, and production environments covering the entire value chain for small-molecule drugs - from early synthesis and process development to analytical testing, formulation, and GMP manufacturing of clinical material.
By partnering with RISE, companies can quickly scale their development capacity up or down without long-term investments in personnel, equipment, or facilities. Our projects are executed in a structured manner, with clear risk management, regulatory awareness, and a focus on data-driven decision-making that stands up to regulatory scrutiny.
Explore our offering in small-molecule drug development or contact us directly to discuss how we can address your challenges.
